• Alzai Health entered a memorandum of understanding with Quanterix on November 13, 2026, to explore earlier Alzheimer's disease identification.
• The proposed collaboration would combine AI-driven risk identification technology with Quanterix's LucentAD blood-based biomarkers to support targeted diagnostic testing.
• The MOU is primarily nonbinding; future commercial arrangements require separate definitive agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzai Health Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611130600NEWSFILECNPR____20261113_323880_1) on November 13, 2026, and is solely responsible for the information contained therein.